{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 52,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/20",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Birtamimab Source: Gertz MA et al... Figures reflect cross-trial comparison and not results from a head-to head study.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "694b3415-1f95-4839-82f8-650adc0d8d0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18d87a22-0679-49fb-8014-4214b925e050",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison table of NXC-201 vs Darzalex, Investigator's Choice, CAEL-101, and Birtamimab across response metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49191bb2-a041-461a-bc07-914fcd089c76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in AL (light chain) Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ac4ad49-0248-4d20-a37d-76a858bd5743",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "44355773-ea3b-4a86-8895-8ba648245920",
      "evidence": "Direct side-by-side clinical data comparison against competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}